Verve Therapeutics announces common stock offering, concurrent private placement

Verve Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock. Concurrent with the public offering, Verve intends to sell, subject to the consummation of the proposed public offering and satisfaction of other customary closing conditions, in a private placement, up to $35M of its common stock to Eli Lilly and Company or, such lesser amount such that Lilly’s beneficial ownership does not exceed 4.9% of the number of shares of common stock to be outstanding immediately following the closing of the public offering and the concurrent private placement. The shares will be sold to Lilly at a price per share equal to the public offering price. Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.